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Summary
Prior to clinical applications, it is critical that risk prediction models are evaluated in independent
studies that did not contribute to model development. While prospective cohort studies provide
a natural setting for model validation, they often ascertain information on some risk factors (e.g.,
an expensive biomarker) in a nested sub-study of the original cohort, typically selected based
on case-control status, and possibly some additional covariates. In this article, we propose an
efficient approach for evaluating discriminatory ability of models using data from all individuals
in a cohort study irrespective of whether they were sampled in the nested sub-study for measuring
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the complete set of risk factors. For evaluation of the Area Under the Curve (AUC) statistics,
we estimate probabilities of risk-scores for cases being larger than those in controls conditional
on partial risk-scores, the component of the risk-score that could be defined based on partial
covariate information. The use of partial risk-scores, as opposed to actual multivariate risk-factor
profiles, allows estimation of the underlying conditional expectations using subjects with complete
covariate information in a non-parametric fashion even when numerous covariates are involved.
We propose an influence function based approach for estimation of the variance of the resulting
AUC statistics. We evaluate finite sample performance of the proposed method and compare it to
an inverse probability weighted (IPW) estimator through extensive simulation studies. Finally, we
illustrate an application of the proposed method for evaluating performance of a lung cancer risk
prediction model using data from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO)
trial.
Key words: area under the curve, discriminatory accuracy, nested case-control study, risk-score, two-phase
studies
1. Introduction
The ultimate goal of a disease risk prediction model is to provide validated tools to patients
and clinicians for making optimal healthcare decisions for disease prevention based on individual
patient characteristics. For a risk prediction model to be clinically useful, it should be first
evaluated in independent studies that did not contribute to the estimation of model parameters.
Model evaluation involves two aspects: model calibration, i.e., evaluate whether the model is
producing unbiased estimates of the disease risk for subjects with different risk factor profiles;
and model discrimination, i.e., the ability of the model to discriminate between cases and controls
(Gail and Pfeiffer, 2005; Chatterjee and others, 2016; Pfeiffer and Gail, 2017).
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Prospective cohort studies, where disease-free individuals are enrolled and followed over time
to observe disease incidence, provide an ideal setting for validation of risk models. However, co-
hort studies often collect data on risk factors using a two-phase design creating complex data
structure. While all the cohort subjects contribute information on some epidemiologic risk factors
(e.g., demographic factors like age, gender, race); information on some expensive covariates, such
as a biomarker, are collected only on a nested sub-study of the original cohort. The sub-sample
is typically stratified with respect to case/control status and certain other covariates that are
observed for all the subjects in the cohort. The methods for analysis of data from such two
phase studies for the purpose of fitting various regression models such as logistic regression or the
Cox proportional hazard model have been well studied. (Prentice, 1986; Breslow and Cain, 1988;
Langholz and Borgan, 1995; Reilley and Pepe, 1995; Scott and Wild, 1997; Langholz and Bor-
gan, 1997; Breslow and Holubkov, 1997; Chatterjee and others, 2003). There has been, however,
limited investigations on how the data from two-phase cohort studies can be efficiently used for
model validation. In this article, we focus on evaluating discriminatory ability of models that can
quantify risks of individuals through underlying risk-scores, i.e., weighted linear combinations
of the risk factors. Such models may include commonly used parametric and semi-parametric
models, such as logistic regression and Cox’s proportional hazard model, where the effects of
covariates are modeled parametrically and risk-scores could be defined by the underlying “linear
predictor” of the model.
For models where disease risks are monotone functions of underlying risk-scores, the popular
measure of Area Under the Curve (AUC) for evaluation of model discriminatory performance can
be defined as the probability that the risk-score for a randomly selected subject with the disease is
higher than that for a randomly selected subject without the disease. For studies that employ two-
phase sampling, one can estimate AUC based only on the second phase study subjects that have
complete risk factor information. In order to correct for the bias due to the complex sampling,
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each subject can be weighted by the inverse of probability of selection (Horvitz and Thompson,
1952). The probability of selection may be known or estimated from the data itself, possibly
to increase efficiency of the analysis. Inverse probability weighted (IPW) estimators have been
widely used for model evaluation in settings with complex sampling design (Cai and Zheng, 2011,
2012; Zheng and others, 2013; Zhou and others, 2013; Yao and others, 2015; Huang, 2016; Zheng
and others, 2017). One can possibly conduct more efficient analysis of model evaluation using
both phases of two-phase studies by imputation of missing risk-factor information for subjects
not selected at the second phase (see e.g., Long and others (2011); Liu and Zhao (2012)). Such an
approach, however, requires parametric model assumption for imputation distribution and may
be particularly of concern in studies of model validation which are supposed to be empirical in
nature.
In this article, we propose an alternative method of estimation of AUC that efficiently uti-
lizes data from both phases of two-phase studies. Our method relies on the general principle of
handling missing data in estimating equations using the conditional expectation operator. In this
method, for the subjects who are not included in the second phase sample, we simply replace their
contribution to the underlying estimating equation with the conditional expectation given their
partial risk-scores, defined as observable component of the risk-scores of the underlying model. By
conditioning on partial risk-scores, instead of observable risk-factor profiles, we achieve efficient
dimension reduction without losing underlying risk information provided by the covariates. The
dimension reduction allows estimation of conditional expectations, using data from subjects with
complete risk-factor information, in a fairly non-parametric fashion even when numerous risk
factors are evaluated in phase-I. We also derive an influence function based asymptotic variance
estimate of our proposed estimator.
This paper is organized as follows: in Section 2, we describe our proposed statistical methodol-
ogy and give an overview of the major results. In Section 3, we assess the finite sample performance
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of the proposed estimator and its standard error estimator and evaluate its efficiency relative to
simple IPW estimator using extensive simulation studies. In Section 4, we present results from an
application of the proposed method for evaluation of a lung cancer risk prediction model using
data from a cohort study that evaluated important biomarkers for inflammation on a nested
case-control study. In Section 5, we conclude the article with a discussion. The mathematical
details of variance calculations, additional simulation results and additional details of real data
analysis are provided in Supplementary Materials.
2. Methods
Suppose a study includes a total of N1 cases and N0 controls (N = N1 + N0). Let X denote
the design vector associated with a set of risk factors included in a risk prediction model for
binary disease outcome and β denote the corresponding vector of risk parameters. We assume
that the model defines risks of individuals in terms of the risk-factors through an underlying
linear predictor, or “risk-score”, in the form S = Xβ. Here X can include individual risk-factors
and possibly their interaction terms as specified by the underlying model. We further assume that
both the model and the underlying risk parameters (β) are pre-specified and have been derived
based on analysis of prior studies and the goal of the current study is only to assess discriminatory
power of the given model. We assume, some risk-factors (e.g., an expensive biomarker) may be
measured only on a sub-sample of the subjects, which may have been selected based on case-
control status and possibly some other covariate characteristics. The risk factors observed on all
the subjects in the cohort are called phase-I risk factors and those that are observed only on the
sub-sample are called phase-II risk factors. Accordingly we can partition X as X = (Z,W ) and
β as β = (βZ , βW ), where Z denote the sub-vector of X observed on all subjects in the study,
W denote the sub-vector of X observed only on the subjects in the second phase sub-sample,
βZ and βW are the risk parameters associated with Z and W respectively. Here, we note that, if
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model involves interaction terms among phase-I and phase-II risk factors, then Z, by definition,
will not include elements for corresponding interaction terms because they are not “observable”
at phase-I.
The Area Under the Curve (AUC) can be defined as δ0 = P [S1 > S0], where S1 and S0 are
the full risk-scores for the cases and controls respectively. Based on the observed and missing
design vector profiles, we can decompose the risk-scores as S = Sobs + Smis = ZβZ + WβW .
For the cases and controls, we express these decompositions as: S1 = S1,obs + S1,mis and S0 =
S0,obs + S0,mis respectively. Here, for cases(controls) included in the second phase sub-sample,
S1(S0) are observed; but for cases(controls) not included only S1,obs(S0,obs) are observed. Let
R1(R0) be the indicator of inclusion of a case(control) in the second phase sub-sample. We assume
subjects may be sampled in the second-phase sample with sampling probability depending case-
control status and possibly some covariates (Z) that are observed for subjects in the entire sample.
Let Z1(Z0) be the vector of these covariates for cases(controls) in the study. We further assume
pi1(Z1) = P [R1 = 1|Z1] and pi0(Z0) = P [R0 = 1|Z0] defined as the sampling probabilities for
the case and controls, respectively, to be known. Some of the covariates in Z1(Z0) could be risk
factors in the models and thus could be included in S1,obs(S0,obs).
When all the risk factors are observed on the entire cohort, i.e., there are no missing risk
factors, the AUC can be estimated by the empirical proportion of case-control pairs for which
the risk-score for the case is greater than that of the control. The underlying estimating equation
can be written in the form:
N1∑
i=1
N0∑
j=1
(I(S1i > S0j) − δ) = 0. DeLong and others (1988) derive a
variance formula for this estimate using general theory of U-statistics.
In the presence of two-phase sampling, the inverse probability weighted estimator of AUC can
be obtained by solving the estimating equations:
N1∑
i=1
N0∑
j=1
R1i
pi1(Z1i)
R0j
pi0(Z0j)
(
I(S1i > S0j)−δ
)
= 0,
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leading to the solution (Huang, 2016):
δˆIPW =
N1∑
i=1
N0∑
j=1
R1i
pi1(Z1i)
R0j
pi0(Z0j)
I(S1i > S0j)
N1∑
i=1
N0∑
j=1
R1i
pi1(Z1i)
R0j
pi0(Z0j)
Suppose N1/N → λ ∈ (0, 1). Using empirical process theory (details in Supplementary Materials),
the influence function representation of this estimator can be derived as:
(δˆIPW−δ0) = 1
N1
N1∑
i=1
R1i
pi1(Z1i)
(
p0(S1i)−δ0
)
+
1
N0
N0∑
j=1
R0j
pi0(Z0j)
(
p1(S0j)−δ0
)
+op(1/
√
N) (2.1)
where pd(S1−d) = ESd [I(S1 > S0)] = PSd [S1 > S0] for d = 0, 1. Consequently, the variance of
δˆIPW can be approximated as:
V ar[δˆIPW ] ≈ 1
N1
E
[(
R1
pi1(Z1)
(
p0(S1)− δ0
))2]
+
1
N0
E
[(
R0
pi0(Z0)
(
p1(S0)− δ0
))2]
(2.2)
A similar variance formula for the IPW estimator is given in Huang (2016). One may estimate
the expectation in each term of (2.2) using the corresponding empirical weighted average using
the information on second phase subjects and the sampling weights.
The inverse probability weighted approach can lead to efficiency loss in the AUC estimation
by discarding the partial risk factor information from the subjects not included in the second
phase sub-sample. To improve efficiency, we propose solving an alternative estimating equation
of the form:
N1∑
i=1
N0∑
j=1
(δˆij − δ) = 0, where δˆijs are the estimators of δijs:
δij = R1iR0jI(S1i > S0j)
+R1i(1−R0j)E[I(S1i > S0j)|S1i, S0j,obs]
+(1−R1i)R0jE[I(S1i > S0j)|S1i,obs, S0j ]
+(1−R1i)(1−R0j)E[I(S1i > S0j)|S1i,obs, S0j,obs] (2.3)
In (2.3), the decomposition of δij into four components correspond to the inclusion status of
the different case-control pairs to the second phase sub-sample. Each term corresponds to taking
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conditional expectation of the term, I(S1 > S0), i.e., the indicator of whether the risk-score
for a case is greater than that of the control, given the observed risk-scores for the case-control
pairs. This approach based on conditioning on the observed risk-scores, and not the observed
multivariate risk-factor profiles, allows us to estimate the conditional expectations in (2.3) in a
fairly non-parametric fashion even when the number of observed risk-factors are relatively large.
We propose to consider fine categories (e.g., deciles) of the observed risk-score and estimate the
conditional expectations empirically based on the second phase sample accounting for sampling
weights. In particular, the conditional expectations are estimated as follows:
Eˆ[I(S1i > S0j)|S1i, S0j,obs] =
N0∑
l=1
R0l
pi0(Z0l)
I(Sc0l,obs = S
c
0j,obs)I(S1i > S0l)
N0∑
l=1
R0l
pi0(Z0l)
I(Sc0l,obs = S
c
0j,obs)
Eˆ[I(S1i > S0j)|S1i,obs, S0j ] =
N1∑
k=1
R1k
pi1(Z1k)
I(Sc1k,obs = S
c
1i,obs)I(S1k > S0j)
N1∑
k=1
R1k
pi1(Z1k)
I(Sc1k,obs = S
c
1i,obs)
Eˆ[I(S1i > S0j)|S1i,obs, S0j,obs] =
N1∑
k=1
N0∑
l=1
R1kR0l
pi1(Z1k)pi0(Z0l)
I(Sc1k,obs = S
c
1i,obs, S
c
0l,obs = S
c
0j,obs)I(S1k > S0l)
N1∑
k=1
N0∑
l=1
R1kR0l
pi1(Z1k)pi0(Z0l)
I(Sc1k,obs = S
c
1i,obs, S
c
0l,obs = S
c
0j,obs)
where Sc1,obs and S
c
0,obs are the categorical versions (e.g., deciles) of the observed risk-score for
cases and controls in the cohort respectively. Plugging in these estimators we get δˆij and the two
phase estimator of AUC can be written as:
δˆTPS =
1
N1N0
N1∑
i=1
N0∑
j=1
δˆij
The main result regarding the asymptotic theory of the estimator is summarized in the fol-
lowing theorem and a sketch of the proof is given in the Supplementary Materials.
Theorem 2.1 Suppose N1/N → λ ∈ (0, 1). Let pd(S1−d) be as defined in (2.1), p(Sd,obs) =
E[pd(S1−d)|S1−d,obs], p(Sd, Sc1−d,obs) = E[I(S1 > S0)|Sd, Sc1−d,obs], p(Scd,obs, Sc1−d,obs) = E[I(S1 >
S0)|Scd,obs, Sc1−d,obs], ψd(Sd) = EZ1,Z0|Scd,obs [(1−pid(Zd))(p(Sd, Sc1−d,obs)−p(Scd,obs, Sc1−d,obs))|Scd,obs]
Evaluating discriminatory accuracy using partial risk-scores in two-phase studies 9
for d = 0, 1. Under mild regularity conditions the influence function representation of δˆTPS can
be written as:
(δˆTPS − δ0) ≈ 1
N1
N1∑
i=1
(
R1ip0(S1i) + (1−R1i)p(S1i,obs) + R1i
pi1i(Z1i)
ψ1(S1i)− δ0
)
+
1
N0
N0∑
j=1
(
R0jp1(S0j) + (1−R0j)p(S0j,obs) + R0j
pi0j(Z0j)
ψ0(S0j)− δ0
)
+ op(1/
√
N)
(2.4)
From (2.4), the asymptotic variance of δˆTPS can be expressed as:
V ar[δˆTPS ] ≈ 1
N1
E
[(
R1p0(S1) + (1−R1)p(S1,obs) + R1
pi1(Z1)
ψ1(S1)− δ0
)2]
+
1
N0
E
[(
R0p1(S0) + (1−R0)p(S0,obs) + R0
pi0(Z0)
ψ0(S0)− δ0
)2]
(2.5)
In (2.5), the two terms correspond to contributions from the cases and controls respectively. Each
subject included in the second phase sample contributes twice to the variability: the first one is
due to their direct contribution to the estimation of the AUC and the second one comes from
their contribution to estimation of the conditional expectations described earlier.
Each expectation term in (2.5) can be estimated using the corresponding empirical average.
Estimates of p0(S1), p1(S0), p(S1,obs), p(S0,obs), ψ1(S1), ψ0(S0) are obtained from the subjects in
the second phase sample by the corresponding weighted averages over case-control pairs within
stratum defined by the observed risk-score categories using the sampling weights.
3. Simulation Study
We conducted extensive simulation studies to assess the finite sample performance of the proposed
estimator in terms of bias, variance and coverage of 95% Wald based confidence intervals and
also relative efficiency gain compared to the IPW estimator.
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3.1 Simulation Design
We simulate data for a cohort study of N=50,000 individuals based on a model involving a
total of 8 independent risk-factors. We assume four of the risk-factors (X1, X2, X3 and X4) are
continuously distributed as standard normal variates, and the other four are binary (X5, X6,
X7 and X8), distributed as Bernoulli random variables each with success probability p = 0.5.
Let X = (X1, X2, X3, X4, X5, X6, X7, X8). Let β be the vector of log-relative risks associated
with these covariates. For each individual we generate an age of disease onset T from a Cox
model of the form λ(t|X = x) = λ0(t)exp(xβ), where λ0(t) = λγtγ−1 is the hazard function
corresponding to Weibull(λ, γ) distribution. The log-relative risk parameters of the model were
chosen to be β = (log(1.1), log(1.1), log(1.1), log(1.1), log(1.2), log(1.2),− log(1.2),− log(1.2))T ,
which correspond to moderate level of associations for each of the individual risk-factors with
the disease. Moreover, the parameters associated with the baseline hazard were chosen such that
the probability of developing the disease by age 50 and 70 years are approximately 5% and 12%
respectively. We generate age of entry for a subject from a discrete uniform distribution in the
range 50 years to 70 years. We also generate a length of observed follow-up from a discrete uniform
distribution in the range 19 years to 21 years. The data generating mechanism assumes that each
subject is disease free at the time of entry into the cohort.
After we simulate data on full cohort, we select a nested case-control sample using alternative
designs and assume that data on two of the risk-factors, X7 and X8, are only available on the sub-
sample. Thus, we assume X = (Z,W ), where Z = (X1, X2, X3, X4, X5, X6) and W = (X7, X8).
Accordingly, β can be partitioned as β = (βZ , βW ) and we define Sobs = ZβZ , Smis = WβW
and S = Sobs + Smis. We further define f to be the variance of Sobs, the partial risk-score,
as a ratio to that of S, the total risk-score, and use it as an index to quantify the relative
importance of the phase-I risk-factors compared to the entire set of risk-factors. For our chosen
β = (log(1.1), log(1.1), log(1.1), log(1.1), log(1.2), log(1.2),− log(1.2),− log(1.2))T , we have f ≈
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0.75. We vary value of f in the set 0.05,0.1,0.2,0.4,0.5,0.75 by varying the underlying values of
the log-relative-risk parameters of the risk factors and the parameters of the baseline hazard in
the model.
We explore two sampling strategies to simulate the subjects in the second phase nested case-
control sample: simple case-control sampling and stratified case-control sampling.
Simple case-control sampling: Here we create a nested case-control study by selecting random
samples of cases and controls from the cohort. We vary the fraction of cases to be sampled in
the second phase study in the range η = 1, 0.75, 0.5, 0.25, 0.1. In each setting, we sample roughly
equal number of controls. The sampling probability of the controls were empirically estimated as
the number of controls sampled as a ratio to the total number in the full cohort.
Stratified case-control sampling: Under this setting, we consider a sampling scheme where
cases and controls were sampled in the second-phase by matching with respect to the partial
risk-scores that could be defined based on the risk-factors observed in the entire cohort. We first
stratify the cohort into ten categories based on deciles of the observed risk-scores among cases
and then draw roughly equal number of cases and controls from each category. As before, we vary
η, the proportion of cases to be sampled at the second phase, over a range. Under this design, we
also determine the sampling probabilities of the controls empirically from our simulation studies.
For each simulation setting, we repeatedly generate the cohort study with complete risk factor
information to obtain 1000 simulated cohort datasets. We compute the AUC from each dataset
as the empirical proportion of case-control pairs for which the risk-score for the case is greater
than that of the control. We compute an average of these 1000 AUC values and consider it to be
the true AUC of the underlying model.
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3.2 Simulation Results
Table 1 shows the simulation results evaluating the performance of the proposed and the IPW
estimators under alternative sampling schemes with sampling fraction for cases 1, 0.5, 0.25 and
f = 0.75. In all the scenarios, both the estimators have very small bias and the confidence intervals
(constructed using influence function based variance estimates) achieve the nominal 95% level.
The percent bias in the standard error estimate is also very small. In all the scenarios, the proposed
estimator is much more efficient compared to the IPW estimator. When the second phase sample
includes all the cases and a random sample of the controls, the proposed approach leads to
approximately 50% efficiency gain. Compared to simple case-control sampling, the straified case-
control sampling of the second phase subjects leads to modest efficiency loss. Similar simulation
tables for f = 0.5 and f = 0.2 are shown in the Supplementary Materials.
Figure 1 shows the relative efficiency of the proposed estimator compared to the IPW estimator
as a function of the fraction of cases sampled (η) under simple case-control sampling of the second
phase subjects. For fixed f , the relative efficiency increases as the fraction of cases sampled at
phase II decreases because the IPW estimator fails to incorporate information from the increasing
number of unselected subjects. Moreover, for fixed fraction of cases sampled, the relative efficiency
increases with increase in f as the observed risk-score explains a larger proportion of the variability
of the full risk-score and the proposed estimator gains efficiency by using the observed risk-score
from all the subjects in the cohort.
4. Data Analysis
We illustrate an application of the proposed method to evaluate the discriminatory performance of
a lung cancer risk prediction model that has a potential clinical application for selecting subjects
for CT-screening. The CT scan procedure, which uses low-dose radiation from x-ray machines
to scan the body in a helical path and produce detailed image of regions inside the body, has
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been demonstrated as an effective method for reducing lung cancer mortality compared to chest
radiography (National Lung Screening Trial Research Team and others, 2011; Gould, 2014).
As a consequence, the US Preventive Services Task Force (USPSTF) recommended annual CT
screening for lung cancer in certain risk factor based subgroups of individuals (Moyer, 2014;
de Koning and others, 2014; McMahon and others, 2014). However, screening is likely to be
more beneficial if the subjects at higher risk of lung cancer can be identified based on individual
risk predictions (i.e., risk based selection) (Bach and Gould, 2012; Bach, 2014; Gould, 2014;
Tammema¨gi, 2015). This can be implemented by developing and validating a comprehensive
lung cancer risk prediction model that includes the major risk factors.
The original model included a host of epidemiologic risk factors: gender, race, education,
BMI, smoking pack-years coded as a categorical variable, number of years since stopped smoking
cigarettes, number of years smoked, binary indicator of > 1 pack/day, presence/absence of em-
physema, lung cancer family history (Katki and others, 2016). The model was developed using
data from the control arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
(PLCO: 1993-2009), which included approximately 39,000 ever smokers in the age range 55-74
years with epidemiologic risk factor information. The variable coding and relative risk information
for these risk factors are provided in Table 3 of Supplementary Materials.
We wanted to evaluate the potential added value of certain inflammation biomarkers into the
model using data that has been collected within the screening arm of the PLCO study. Information
on four biomarkers, C-Reactive Protein [CRP], serum amyloid A [SAA], soluble tumor necrosis
factor receptor 2 [sTNFRII] and monokine induced by gamma interferon [CXCL9/MIG], were
collected in two nested case-control studies within the screening arm of the PLCO study: the
discovery study and the replication study (Shiels and others, 2013, 2015). The discovery study
included 960 ever smokers aged 55-74 years (500 cases and 460 controls) and the replication study
included 929 ever smokers aged 55-74 years (468 cases and 461 controls). Among these biomarkers,
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CRP has been shown to be consistently associated with lung cancer (Chaturvedi and others, 2010;
Pine and others, 2011; Leuzzi and others, 2016), while the other three were identified as most
promising ones among a larger set of biomarkers studied in the discovery and replication samples.
We obtained the relative risk parameters of the four biomarkers, after adjustment of the other
epidemiologic factors, using the discovery sample (see Table 3 of Supplementary Materials for
coding of these variable and estimates of associated risk parameters). These estimates together
with those obtained for the traditional epidemiologic factors from the control arm of the PLCO
study provided a combined model for predicting lung cancer risk based on the epidemiologic risk
factors and biomarkers.
In the current analysis, we evaluated discriminatory accuracy of the combined model using
the screening arm of the PLCO study and the replication biomarker study. Since neither the
epidemiologic risk-factors from the screening cohort nor the biomarker information from the
replication case-control study was utilized for model building, the resulting two-phase study can
be assumed to be independent of model development.
We divide the PLCO screening arm participants into four age categories: 6 59 years, 60-64
years, 65-69 years, > 70 years and evaluate the discriminatory performance in these four sub-
cohorts defined by those categories. Table 2 shows the AUC estimates and the associated standard
errors in the four sub-cohorts based on three combinations of risk factors: (i) epidemiologic risk
factors only, (ii) epidemiologic risk factors and C-reactive protein and (iii) epidemiologic risk
factors and all four inflammation biomarkers. For computing the proposed AUC estimator, we
stratify the partial risk-score observed in phase-I into six categories based on sextiles. For the
epidemiologic risk factor only model, we evaluated standard AUC estimator based on all smokers
in the entire PLCO screening arm (Phase I sample). From results reported in Table 2 we observe
that AUC estimates for each type of model substantially decreased from younger to the older age
groups. For risk factor combinations (ii) and (iii), comparison of the proposed and IPW estimators
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shows that while point estimates were similar, the precision of the proposed estimator was much
higher across all the settings. We observe that the inclusion of inflammation biomarkers leads to
limited improvement of AUC irrespective of the age groups.
5. Discussion
In this article, we propose an efficient and robust estimator of AUC statistics in the setting of
two-phase study designs. Our method combines complete risk factor information from the second
phase sample and partial risk factor information from subjects not included in the second phase.
We have derived an explicit formula for asymptotic variance of the proposed estimator. The
results from the simulation studies and the real data analysis demonstrate the efficiency gain
that our method achieves compared to the IPW approach.
The estimation of conditional probabilities requires adjustment for potential non-random
sampling of the second phase subjects. We perform this step using inverse probability weighting
assuming the selection probabilities (i.e., sampling weights) are known. In real data settings, it
may be complicated to obtain these selection probabilities and they may need to be obtained
through post-hoc estimation under parametric assumptions on the selection mechanism. In our
real data application, we use sampling weights derived from a logistic regression model of inclusion
on case/control status and other covariates (see Supplementary Materials). Our method may be
subject to bias if the true selection mechanism does not belong to the class of parametric models
considered for post-hoc estimation. Even when the selection model is correct, the method needs
to appropriately account for the uncertainty of the post-hoc estimation of selection probabilities.
The setting we consider has a close connection with a recent study conducted by Zheng and
others (2017). In a time-to event setting, they propose a weighted semiparametric likelihood ap-
proach to estimate the relative risks of the risk factors and the model evaluation statistics (e.g.,
time dependent AUC) using information from the second phase subjects. The method incorpo-
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rates information from Phase I subjects through estimation of selection probabilities conditional
on observed risk-factor information. The non-parametric estimation approach they consider, how-
ever, could break down due to curse of dimensionality when numerous covariates are evaluated at
the Phase I sample itself. We consider a simpler setting where we use only the disease status in-
formation of each subject in the cohort ignoring the information on follow-up time. In the future,
we plan to extend our partial risk-score based approach to evaluate the AUC and possibly other
model evaluation statistics in a time-to-event setting taking into account censoring and follow-up
information.
In summary, the strengths of our approach are its practical usefulness and ease of implemen-
tation with numerous risk factors. The efficient dimension reduction achieved through partial
risk-scores allows us to estimate model evaluation statistics in a non-parametric manner, which
is particularly useful in model validation studies that are supposed to be empirical in nature.
6. Supplementary Material
The reader is referred to the Supplementary Materials for technical appendices, additional sim-
ulations and additional details of real data application.
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Fig. 1. Relative efficiency of our proposed estimator compared to the IPW estimator as a function of the
fraction of cases sampled (η) under random case-control sampling of the second phase subjects. Different
lines correspond to different values of f characterizing different proportions of variability of the full
risk-score explained by the observed risk-score.
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Table 1. Simulation studies evaluating performance of the proposed and the IPW estimators of
AUC estimation under two-phase studies. Results are shown under alternative sampling schemes
with varying sampling probabilities and a fixed value of f = 0.75, proportion of variability of the
full risk score explained by the observed risk score. The true value of AUC of the underlying model
is 0.577. Relative efficiency (RE) of the AUC estimates are reported in reference to standard
estimate of AUC obtained using information on all risk factors for all subjects in the cohort.
Percent bias in the estimation of standard errors of AUC using the influence function based
variance estimate are also reported.
RE (compared Percent bias
Bias to full cohort) in SE estimate Coverage
Sampling scheme TPS IPW TPS IPW TPS IPW TPS IPW
Simple case-control sampling
Sampling fraction of cases 1
Case-control ratio 1:1 9.56 × 10−5 0.0002 0.89 0.58 -3.92 -3.17 0.96 0.94
Sampling fraction of cases 0.5
Case-control ratio 1:1 0.0002 −4.5× 10−5 0.6 0.28 -1.61 -1.1 0.95 0.96
Sampling fraction of cases 0.25
Case-control ratio 1:1 0.0002 0.0004 0.41 0.14 -5.33 -0.78 0.96 0.95
Stratified case-control sampling
Sampling fraction of cases 1
Case-control ratio 1:1 7.08 × 10−5 −6.39× 10−5 0.73 0.5 5.36 2.94 0.94 0.94
Sampling fraction of cases 0.5
Case-control ratio 1:1 5.74 × 10−5 0.0001 0.6 0.28 -1.61 -3.33 0.96 0.96
Sampling fraction of cases 0.25
Case-control ratio 1:1 -0.0002 0.0001 0.4 0.13 -3.95 0 0.96 0.95
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Table 2. Age category specific AUC estimates and standard errors for three alternative risk mod-
els: (i) epidemiologic risk factors only, (ii) epidemiologic risk factors and C-reactive protein,
(iii) epidemiologic risk factors and four inflammation markers. Phase I subjects are the ever-
smokers aged 55-74 years in the screening arm of the PLCO Trial; Phase II subjects are those
ever-smokers aged 55-74 years included in the replication study (nested case-control study within
PLCO screening arm). For epidemiologic risk factor only model, the standard AUC estimator
based on Phase I sample is reported.
AUC estimate
(standard deviation)
Epidemiologic Epidemiologic Epidemiologic
Number of subjects risk factors risk factors + risk factors +
(Number of cases) only CRP 4 inflammation markers
Age (in years) Phase I Phase II IPW TPS IPW TPS
6 59 13,443 208 0.799 0.777 0.803 0.78 0.804
(321) (103) (0.011) (0.047) (0.028) (0.046) (0.027)
60-64 12,054 277 0.761 0.766 0.752 0.762 0.75
(459) (140) (0.011) (0.031) (0.023) (0.031) (0.023)
65-69 8669 277 0.777 0.802 0.801 0.8 0.8
(489) (140) (0.01) (0.034) (0.023) (0.035) (0.024)
> 70 4632 167 0.709 0.707 0.715 0.719 0.725
(277) (85) (0.015) (0.05) (0.026) (0.049) (0.025)
Total 38,798 929
(1546) (468)
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1. Variance of the two-phase estimator
In this section we give a sketch of proof for Theorem 2.1 of the manuscript. We derive the influence
function representation of δˆTPS using the following steps:
Step 1: Note that:
(δˆTPS − δ0) = 1
N1N0
N1∑
i=1
N0∑
j=1
(δij − δ0) + 1
N1N0
N1∑
i=1
N0∑
j=1
(δˆij − δij) (1.1)
∗To whom correspondence should be addressed: nchatte2@jhu.edu
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Step 2: The first term in equation 1.1 can be expressed as:
1
N1N0
N1∑
i=1
N0∑
j=1
(δij − δ0)
=
1
N1N0
N1∑
i=1
N0∑
j=1
R1iR0j(I(S1i > S0j)− δ0)
+
1
N1N0
N1∑
i=1
N0∑
j=1
R1i(1−R0j)(E[I(S1i > S0j)|S0i, S0j,obs]− δ0)
+
1
N1N0
N1∑
i=1
N0∑
j=1
(1−R1i)R0j(E[I(S1i > S0j)|S1i,obs, S0j ]− δ0)
+
1
N1N0
N1∑
i=1
N0∑
j=1
(1−R1i)(1−R0j)(E[I(S1i > S0j)|S1i,obs, S0j,obs]− δ0) (1.2)
The first term in equation 1.2 can be expressed as:
1
N1N0
N1∑
i=1
N0∑
j=1
R1iR0j(I(S1i > S0j)− δ0)
=
∫
(R1,S1)
∫
(R0,S0)
R1R0(I(S1 > S0)− δ0)dF (N1)(R1,S1)dF
(N0)
(R0,S0)
≈
∫
(R1,S1)
∫
(R0,S0)
R1R0(I(S1 > S0)− δ0)dF(R0,S0)dF
(N1)
(R1,S1)
+
∫
(R0,S0)
∫
(R1,S1)
R1R0(I(S1 > S0)− δ0)dF(R1,S1)dF
(N0)
(R0,S0)
by von Mises expansion
=
1
N1
N1∑
i=1
R1iEZ0 [pi0(Z0)ES0,mis|S0,obs [(I(S1i > S0)− δ0)|S0,obs]]
+
1
N0
N0∑
j=1
R0jEZ1 [pi1(Z1)ES1,mis|S1,obs [(I(S1 > S0j)− δ0)|S1,obs]]
The second term of equation 1.2 can be expressed as:
1
N1N0
N1∑
i=1
N0∑
j=1
R1i(1−R0j)(E[I(S1i > S0j)|S1i, S0j,obs]− δ0)
=
∫
(R1,S1)
∫
(R0,S0,obs)
R1(1−R0)(E[I(S1 > S0)|S1, S0,obs]− δ0)dF (N1)(R1,S1)dF
(N0)
(R0,S0,obs)
≈
∫
(R1,S1)
∫
(R0,S0,obs)
R1(1−R0)(E[I(S1 > S0)|S1, S0,obs]− δ0)dF(R0,S0,obs)dF
(N1)
(R1,S1)
+
∫
(R0,S0,obs)
∫
(R1,S1)
R1(1−R0)(E[I(S1 > S0)|S1, S0,obs]− δ0)dF(R1,S1)dF
(N0)
(R0,S0,obs)
=
1
N1
N1∑
i=1
R1iEZ0 [(1− pi0(Z0))ES0,mis|S0,obs [(I(S1i > S0)− δ0)|S0,obs]]
+
1
N0
N0∑
j=1
(1−R0j)EZ1 [pi1(Z1)ES1,mis|S1,obs [ES0,mis|S0,obs [(I(S1 > S0)− δ0)|S0j,obs]|S1,obs]]
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The third term of equation 1.2 can be expressed as:
1
N1N0
N1∑
i=1
N0∑
j=1
(1−R1i)R0j(E[I(S1i > S0j)|S1i,obs, S0j ]− δ0)
=
∫
(R1,S1,obs)
∫
(R0,S0)
(1−R1)R0(E[I(S1 > S0)|S1,obs, S0]− δ0)dF (N1)(R1,S1,obs)dF
(N0)
(R0,S0)
≈
∫
(R1,S1,obs)
∫
(R0,S0)
(1−R1)R0(E[I(S1 > S0)|S1,obs, S0]− δ0)dF(R0,S0)dF
(N1)
(R1,S1,obs)
+
∫
(R0,S0)
∫
(R1,S1,obs)
(1−R1)R0(E[I(S1 > S0)|S1,obs, S0]− δ0)dF(R1,S1,obs)dF
(N0)
(R0,S0)
=
1
N1
N1∑
i=1
(1−R1i)EZ0 [pi0(Z0)ES0,mis|S0,obs [ES1,mis|S1,obs [(I(S1i > S0)− δ0)|S1i,obs]|S0,obs]]
+
1
N0
N0∑
j=1
R0jEZ1 [(1− pi1(Z1))ES1,mis|S1,obs [(I(S1 > S0j)− δ0)|S1,obs]]
The fourth term of equation 1.2 can be expressed as:
1
N1N0
N1∑
i=1
N0∑
j=1
(1−R1i)(1−R0j)(E[I(S1i > S0j)|S1i,obs, S0j,obs]− δ0)
=
∫
(R1,S1,obs)
∫
(R0,S0,obs)
(1−R1)(1−R0)(E[I(S1 > S0)|S1,obs, S0,obs]− δ0)dF (N1)(R1,S1,obs)dF
(N0)
(R0,S0,obs)
=
∫
(R1,S1,obs)
∫
(R0,S0,obs)
(1−R1)(1−R0)(E[I(S1 > S0)|S1,obs, S0,obs]− δ0)dF(R0,S0,obs)dF
(N1)
(R1,S1,obs)
+
∫
(R0,S0,obs)
∫
(R1,S1,obs)
(1−R1)(1−R0)(E[I(S1 > S0)|S1,obs, S0,obs]− δ0)dF(R1,S1,obs)dF
(N0)
(R0,S0,obs)
=
1
N1
N1∑
i=1
(1−R1i)EZ0 [(1− pi0(Z0))ES0,mis|S0,obs [ES1,mis|S1,obs [(I(S1i > S0)− δ0)|S1i,obs]|S0,obs]]
+
1
N0
N0∑
j=1
(1−R0j)EZ1 [(1− pi1(Z1))ES1,mis|S1,obs [(ES0,mis|S0,obs [I(S1 > S0j)− δ0)|S0j,obs]|S1,obs]]
Adding up all the terms leads to:
1
N1N0
N1∑
i=1
N0∑
j=1
(δij − δ0)
=
1
N1
N1∑
i=1
R1i(p0(S1i)− δ0) + 1
N0
N0∑
j=1
R0j(p1(S0j)− δ0)
+
1
N1
N1∑
i=1
(1−R1i)(p(S1i,obs)− δ0) + 1
N0
N0∑
i=1
(1−R0j)(p(S0j,obs)− δ0)
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where pd(S1−d) = ESd [I(S1 > S0)] = PSd [S1 > S0], p(Sd,obs) = E[pd(S1−d)|Sd,obs] for d = 0, 1.
We assume: p(Sd,obs) ≈ p(Scd,obs) for d = 0, 1.
Step 3: The second term in equation 1.1 can be expressed as:
1
N1N0
N1∑
i=1
N0∑
j=1
(δˆij − δij)
=
1
N1N0
N1∑
i=1
N0∑
j=1
R1i(1−R0j)

N0∑
l=1
R0l
pi0(Z0l)
I(Sc0l,obs = S
c
0j,obs){I(S1i > S0l)− p(S1i, S0j,obs)}
N0∑
l=1
R0l
pi0(Z0l)
I(Sc0l,obs = S
c
0j,obs)

+
1
N1N0
N1∑
i=1
N0∑
j=1
(1−R1i)R0j

N1∑
k=1
R1k
pi1(Z1k)
I(Sc1k,obs = S
c
1i,obs){I(S1k > S0j)− p(S1i,obs, S0j)}
N1∑
k=1
R1k
pi1(Z1k)
I(Sc1k,obs = S
c
1i,obs)

+
1
N1N0
N1∑
i=1
N0∑
j=1
(1−R1i)(1−R0j)
×

N1∑
k=1
N0∑
l=1
R1kR0l
pi1(Z1k)pi0(Z0l)
I(Sc1k,obs = S
c
1i,obs, S
c
0l,obs = S
c
0j,obs){I(S1k > S0l)− p(S1i,obs, S0j,obs)}
N1∑
k=1
N0∑
l=1
R1kR0l
pi1(Z1k)pi0(Z0l)
I(Sc1k,obs = S
c
1i,obs, S
c
0l,obs = S
c
0j,obs)

(1.3)
Define: p(S1, S0,obs) = E[I(S1 > S0)|S1, S0,obs], p(S1,obs, S0) = E[I(S1 > S0)|S1,obs, S0],
p(S1,obs, S0,obs) = E[I(S1 > S0)|S1,obs, S0,obs]. We assume the following: p(S1, S0,obs) ≈ p(S1, Sc0,obsc),
p(S1,obs, S0) ≈ p(Sc1,obs, S0) and p(S1,obs, S0,obs) ≈ p(Sc1,obs, Sc0,obs). Let qd(scd,obs) = E[I(Scd,obs =
scd,obs)] = P [S
c
d,obs = s
c
d,obs] for d = 0, 1. Note that E[p(Sd, S1−d,obs)|Sd,obs, S1−d,obs] = p(Sd,obs, S1−d,obs)
for d = 0, 1.
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The ratio term within first bracket in the first term in equation 1.3 can be expressed as:
N0∑
l=1
R0l
pi0(Z0l)
I(Sc0l,obs = S
c
0j,obs){I(S1i > S0l)− p(S1i, S0j,obs)}
N0∑
l=1
R0l
pi0(Z0l)
I(Sc0l,obs = S
c
0j,obs)
≈ 1
q0(Sc0j,obs)
1
N0
N0∑
l=1
R0l
pi0(Z0l)
I(Sc0l,obs = S
c
0j,obs){I(S1i > S0l)− p(S1i, S0j,obs)} (1.4)
The ratio term within first bracket in the second term in equation 1.3 can be written as:
N1∑
k=1
R1k
pi1(Z1k)
I(Sc1k,obs = S
c
1i,obs){I(S1k > S0j)− p(S1i,obs, S0j)}
N1∑
k=1
R1k
pi1(Z1k)
I(Sc1k,obs = S
c
1i,obs)
≈ 1
q1(Sc1i,obs)
1
N1
N1∑
k=1
R1k
pi1(Z1k)
I(Sc1k,obs = S
c
1i,obs){I(S1k > S0j)− p(S1i,obs, S0j)} (1.5)
The ratio term within first bracket in the third term in equation 1.3 can be written as:
N1∑
k=1
N0∑
l=1
R1kR0l
pi1(Z1k)pi0(Z0l)
I(Sc1k,obs = S
c
1i,obs, S
c
0l,obs = S
c
0j,obs){I(S1k > S0l)− p(S1i,obs, S0j,obs)}
N1∑
k=1
N0∑
l=1
R1kR0l
pi1(Z1k)pi0(Z0l)
I(Sc1k,obs = S
c
1i,obs, S
c
0l,obs = S
c
0j,obs)
≈ 1
q1(Sc1i,obs)
1
N1
N1∑
k=1
(
R1k
pi1(Z1k)
I(Sc1k,obs = S
c
1i,obs)ES0|Sc0,obs=Sc0j,obs [(I(S1k > S0)− p(S1i,obs, S0j,obs))|S
c
0,obs = S
c
0j,obs]
)
+
1
q0(Sc0j,obs)
1
N0
N0∑
l=1
(
R0l
pi0(Z0l)
I(Sc0l,obs = S
c
0j,obs)ES1|Sc1,obs=Sc1i,obs [(I(S1 > S0l)− p(S1i,obs, S0j,obs))|S
c
1,obs = S
c
1i,obs]
)
(1.6)
Adding equations 1.4, 1.5 and 1.6 and exchanging summations we have:
1
N1N0
N1∑
i=1
N0∑
j=1
(δˆij − δij)
≈ 1
N1
N1∑
k=1
R1k
pi1k
 1
N1N0
N1∑
i=1
N0∑
j=1
I(Sc1k,obs = S
c
1i,obs)
q1(Sc1i,obs)
[
(1−R1i)R0j(I(S1k > S0j)− p(S1i,obs, S0j))
+ (1−R1i)(1−R0j)ES0|Sc0,obs=Sc0j,obs [(I(S1k > S0)− p(S1i,obs, S0j,obs))|S
c
0,obs = S
c
0j,obs]
])
+
1
N0
N0∑
l=1
R0l
pi0l
 1
N1N0
N1∑
i=1
N0∑
j=1
I(Sc0l,obs = S
c
0j,obs)
q0(Sc0j,obs)
[
R1i(1−R0j)(I(S1i > S0l)− p(S1i, S0j,obs))
+ (1−R1i)(1−R0j)ES1|Sc1,obs=Sc1i,obs [(I(S1 > S0l)− p(S1i,obs, S0j,obs))|S
c
1,obs = S
c
1i,obs]
])
(1.7)
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Using Strong Law of Large Numbers, we approximate the innermost two double-average terms
in the above two terms in equation 1.7 with the corresponding expectation. For the first double
average we compute the expectation in two pieces. The first piece:
E
[
I(Sc1,obs = S
c
1k,obs)
q1(Sc1,obs)
(1−R1)R0(I(S1k > S0)− p(Sc1,obs, S0))
]
= E
[
(1−R1)R0(I(S1k > S0)− p(Sc1,obs, S0))|Sc1,obs = Sc1k,obs
]
= EZ1,Z0|Sc1,obs=Sc1k,obs [(1− pi1(Z1))pi0(Z0)E[I(S1k > S0)− p(S
c
1,obs, S0))|S0,obs, Sc1,obs = Sc1k,obs]|Sc1,obs = Sc1k,obs]
= EZ1,Z0|Sc1,obs=Sc1k,obs [(1− pi1(Z1))pi0(Z0)E[I(S1k > S0)− p(S
c
1k,obs, S0))|S0,obs, Sc1,obs = Sc1k,obs]|Sc1,obs = Sc1k,obs]
= EZ1,Z0|Sc1,obs=Sc1k,obs [(1− pi1(Z1))pi0(Z0)(p(S1k, S0,obs)− p(S
c
1k,obs, S0,obs))|Sc1,obs = Sc1k,obs]
= EZ1,Z0|Sc1,obs=Sc1k,obs [(1− pi1(Z1))pi0(Z0)(p(S1k, S
c
0,obs)− p(Sc1k,obs, Sc0,obs))|Sc1,obs = Sc1k,obs]
The second piece:
E
[
I(Sc1,obs = S
c
1k,obs)
q1(Sc1,obs)
(1−R1)(1−R0)ES0|Sc0,obs [(I(S1k > S0)− p(S
c
1,obs, S
c
0,obs))|Sc0,obs]
]
= E[(1−R1)(1−R0)ES0|Sc0,obs [(I(S1k > S0)− p(S
c
1,obs, S
c
0,obs))|Sc0,obs]|Sc1,obs = Sc1k,obs]
= E[(1−R1)(1−R0)(p(S1k, Sc0,obs)− p(Sc1,obs, Sc0,obs))|Sc1,obs = Sc1k,obs]
= E[(1−R1)(1−R0)(p(S1k, Sc0,obs)− p(Sc1k,obs, Sc0,obs))|Sc1,obs = Sc1k,obs]
= EZ1,Z0|Sc1,obs=Sc1k,obs [(1− pi1(Z1))(1− pi0(Z0))(p(S1k, S
c
0,obs)− p(Sc1k,obs, Sc0,obs))|Sc1,obs = Sc1k,obs]
We can similarly deal with the second double average in equation 1.7. Hence, equation 1.7
can be further simplified to:
1
N1N0
N1∑
i=1
N0∑
j=1
(δˆij − δij)
≈ 1
N1
N1∑
k=1
R1k
pi1k
EZ1,Z0|Sc1,obs=Sc1k,obs [(1− pi1(Z1))(p(S1k, S
c
0,obs)− p(Sc1k,obs, Sc0,obs))|Sc1,obs = Sc1k,obs]
+
1
N0
N0∑
l=1
R0l
pi0l
EZ1,Z0|Sc0,obs=Sc0l,obs [(1− pi0(Z0))(p(S
c
1,obs, S0l)− p(Sc1,obs, Sc0l,obs))|Sc0,obs = Sc0l,obs]
=
1
N1
N1∑
k=1
R1k
pi1k
ψ1(S1k) +
1
N0
N0∑
l=1
R0l
pi0l
ψ0(S0l)
Evaluating discriminatory accuracy using partial risk-scores in two-phase studies 7
where,
ψ1(S1) = EZ1,Z0|Sc1,obs [(1− pi1(Z1))(p(S1, Sc0,obs)− p(Sc1,obs, Sc0,obs))|Sc1,obs]
ψ0(S0) = EZ1,Z0|Sc0,obs [(1− pi0(Z0))(p(Sc1,obs, S0)− p(Sc1,obs, Sc0,obs))|Sc0,obs]
Step 4: Plugging in the results in Step 2 and Step 3 in Step 1 we have:
(δˆTPS − δ0) ≈ 1
N1
N1∑
i=1
R1i(p0(S1i)− δ0) + 1
N0
N0∑
j=1
R0j(p1(S0j)− δ0)
+
1
N1
N1∑
i=1
(1−R1i)(p(S1i,obs)− δ0) + 1
N0
N0∑
i=1
(1−R0j)(p(S0j,obs)− δ0)
+
1
N1
N1∑
i=1
R1i
pi1i
ψ1(S1i) +
1
N0
N0∑
j=1
R0j
pi0j
ψ0(S0j)
=
1
N1
N1∑
i=1
(
R1ip0(S1i) + (1−R1i)p(S1i,obs) + R1i
pi1i
ψ1(S1i)− δ0
)
+
1
N0
N0∑
j=1
(
R0jp1(S0j) + (1−R0j)p(S0j,obs) + R0j
pi0j
ψ0(S0j)− δ0
)
This gives the influence function representation of δˆTPS . The derivation of the asymptotic variance
formula clearly follows from this step:
V ar[δˆTPS ] ≈ 1
N1
E
[(
R1p0(S1) + (1−R1)p(S1,obs) + R1
pi1(Z1)
ψ1(S1)− δ0
)2]
+
1
N0
E
[(
R0p1(S0) + (1−R0)p(S0,obs) + R0
pi0(Z0)
ψ0(S0)− δ0
)2]
An estimate of the asymptotic variance can be written as follows:
ˆV ar[δˆTPS ] ≈ 1
N21
N1∑
i=1
(
R1ipˆ0(S1i) + (1−R1i)pˆ(S1i,obs) + R1i
pi1(Z1i)
ψˆ1(S1i)− δˆTPS
)2
+
1
N20
N0∑
j=1
(
R0j pˆ1(S0j) + (1−R0j)pˆ(S0j,obs) + R0j
pi0(Z0j)
ψˆ0(S0j)− δˆTPS
)2
Here, pˆ0(S1), pˆ1(S0), pˆ(S1,obs), pˆ(S0,obs), ψˆ1(S1) and ψˆ0(S0) are estimated empirically using the
data from the second phase subjects after adjustment for non-random sampling using sampling
weights.
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2. Variance of the IPW estimator
The IPW estimator of AUC, denoted by δˆIPW is obtained by solving the estimating equation:
N1∑
i=1
N0∑
j=1
R1iR0j
pi1(Z1i)pi0(Z0j)
(I(S1i > S0j)− δ) = 0. Note that:
(δˆIPW − δ0) = 1
N1N0
N1∑
i=1
N0∑
j=1
R1iR0j
pi1(Z1i)pi0(Z0j)
(I(S1i > S0j)− δ0) + op(1/
√
N)
The first term can be expressed as a functional of the corresponding empirical distribution func-
tions: θ(F
(N1)
S1
, F
(N0)
S0
) =
∫
S1
∫
S0
R1R0
pi1(Z1)pi0(Z0)
(I(S1 > S0)− δ0) dF (N1)S1 dF
(N0)
S0
. We also note that
θ(FS1 , FS0) = 0, where FS1 and FS0 are the true distribution functions. A linear von Mises expan-
sion of this term leads to the following:
∫
S1
∫
S0
R1R0
pi1(Z1)pi0(Z0)
(I(S1 > S0)− δ0) dF (N1)S1 dF
(N0)
S0
≈
1
N1
N1∑
i=1
R1i
pi1(Z1i)
(ES0 [I(S1i > S0)]−δ0)+
1
N0
N0∑
j=1
R0j
pi0(Z0j)
(ES1 [I(S1 > S0j)]−δ0). This is the influ-
ence function representation of the estimator. The derivation of the asymptotic variance formula
clearly follows from this step by noting that each term in the influence function representation
has mean 0. The formula and an estimate of the asymptotic variance can be written as follows:
V ar[δˆIPW ] ≈ 1
N1
E
[(
R1
pi1(Z1)
(
p0(S1)− δ0
))2]
+
1
N0
E
[(
R0
pi0(Z0)
(
p1(S0)− δ0
))2]
ˆV ar[δˆIPW ] ≈ 1
N21
N1∑
i=1
(
R1i
pi1(Z1i)
(
pˆ0(S1i)− δˆIPW
))2
+
1
N20
N0∑
j=1
(
R0j
pi0(Z0j)
(
pˆ1(S0j)− δˆIPW
))2
pˆ0(S1) and pˆ1(S0) are estimated empirically using the data from the second phase subjects after
adjustment for non-random sampling using sampling weights.
3. Additional details of simulation study
3.1 Computation of sampling weights
In simple case-control sampling, the sampling weights for the cases are same and is given by the
fraction of cases (η) sampled in the second phase study. The sampling weights for the controls
are also same and is the ratio of the number of controls sampled in the second phase and the
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total number of controls in the cohort.
In stratified case-control sampling, the sampling weights for the cases is η. We denote by
c0, . . . , c10 the decile cutpoints of the observed riskscore among cases with c0 = −∞ and c10 =
∞. The sampling weights for controls in the jth decile is 0.1ηN1/N0P [cj < S0,obs 6 cj+1],
j = 0, . . . , 10. The sampling weights are estimated empirically by estimating cj and P [cj <
S0,obs 6 cj+1] from each simulation study.
3.2 Additional simulation results
Tables 1 and 2 show the additional simulation results for the cases f = 0.5 and f = 0.2. The
relative efficiency of the proposed two-phase estimator compared to the IPW estimator is smaller
for lower values of f due to lower contribution of the variability of the observed risk-score to the
variability of the full risk-score. The other performance characteristics are qualitatively similar
to the simulation results for f = 0.75 reported in the manuscript.
4. Additional Details of Data Analysis
4.1 Derivation of sampling weights
We derive the sampling weights by fitting a logistic regression model of the indicator of inclusion
of a PLCO screening arm participant to the replication study on the case/control status and the
following covariates: interaction of age categories (6 59 years, 60-64 years, 65-69 years, > 70 years)
and gender (female = 1, male = 0); observed follow-up in 1 year categories; interaction of age
categories and smoking pack-year categories and smoking status (current = 1 and former = 2);
interaction of age categories and smoking pack-year categories and number of years since stopped
smoking; categorical version of year of randomization (levels: 1993-1995, 1995-1997, 1997-1999,
1999-2001) and interactions of all the above covariates with case/control status.
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4.2 Derivation of relative risk
Table 3 shows the age adjusted relative risks corresponding to the risk factors of three combina-
tions: (i) epidemiologic risk factors, (ii) epidemiological risk factors and C-reactive protein, (iii)
epidemiological risk factors and four inflammation biomarkers. The relative risks for the epidemi-
ologic risk factors were reported based on the information from the ever-smokers in the control
arm of PLCO Trial (Katki and others, 2016). Since information on inflammation biomarkers were
not available from those subjects, the relative risks of epidemiologic risk factors for models (ii)
and (iii) are not adjusted for inflammation biomarkers.
For the risk factor combination (ii), the relative risk for C-Reactive Protein (CRP) was ap-
proximated based on a logistic regression model of case/control status on the quartiles of CRP,
categorical age variable (levels: 6 59 years, 60-64 years, 65-69 years, > 70 years), gender, race,
education status, natural logarithm of BMI, smoking pack-year categories, natural logarithm of
sum of 1 and smoking quit years, total number of years the subject smoked, indicator of > 1
pack/day smoked, presence/absence of emphysema/COPD, lung cancer family history, categor-
ical version of year of randomization (levels: 1993-1995, 1995-1997, 1997-1999, 1999-2001). For
the risk factor combination (iii), the relative risks of all the four inflammation markers were ap-
proximated from another logistic regression model of case/control status on the quartile versions
of the four biomarkers and the other variables as specified in the above model. Both these models
were based on the discovery study.
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Table 1. Simulation studies evaluating performance of the proposed and the IPW estimators of
AUC estimation under two-phase studies. Results are shown under alternative sampling schemes
with varying sampling probabilities and a fixed value of f = 0.5, the proportion of variability of the
full risk-score explained by the partial risk score. The true value of AUC of the underlying model
is 0.596. Relative efficiency (RE) of the AUC estimates are reported in reference to standard
estimate of AUC obtained using information on all risk factors for all subjects in the cohort.
Percent bias in the estimation of standard errors of AUC using the influence function based
variance estimate are also reported.
RE (compared Percent bias
Bias to full cohort) in SE estimate Coverage
Sampling scheme TPS IPW TPS IPW TPS IPW TPS IPW
Simple case-control sampling
Sampling fraction of cases 1
Case-control ratio 1:1 5.85× 10−5 0.0002 0.61 0.49 3.33 2.99 0.94 0.94
Sampling fraction of cases 0.5
Case-control ratio 1:1 0.0004 0.0005 0.4 0.26 -2.7 0 0.96 0.95
Sampling fraction of cases 0.25
Case-control ratio 1:1 0.0002 0.0005 0.19 0.13 4.63 0.76 0.95 0.95
Stratified case-control sampling
Sampling fraction of cases 1
Case-control ratio 1:1 0.0001 0.0002 0.68 0.56 -1.75 -4.76 0.95 0.95
Sampling fraction of cases 0.5
Case-control ratio 1:1 0.0001 2.36× 10−5 0.38 0.26 0 -1.09 0.95 0.96
Sampling fraction of cases 0.25
Case-control ratio 1:1 0.0003 5.95× 10−5 0.21 0.13 0 -0.77 0.96 0.95
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Table 2. Simulation studies evaluating performance of the proposed and the IPW estimators of
AUC estimation under two-phase studies. Results are shown under alternative sampling schemes
with varying sampling probabilities and a fixed value of f = 0.2, proportion of variability of the
full risk-score explained by the partial risk-score. The true value of AUC of the underlying model
is 0.646. Relative efficiency (RE) of the AUC estimates are reported in reference to standard
estimate of AUC obtained using information on all risk factors for all subjects in the cohort.
Percent bias in the estimation of standard errors of AUC using the influence function based
variance estimate are also reported.
RE (compared Percent bias
Bias to full cohort) in SE estimate Coverage
Sampling scheme TPS IPW TPS IPW TPS IPW TPS IPW
Simple case-control sampling
Sampling fraction of cases 1
Case-control ratio 1:1 8.66× 10−5 0.0001 0.59 0.55 0 -1.61 0.95 0.95
Sampling fraction of cases 0.5
Case-control ratio 1:1 -0.0004 -0.0005 0.31 0.28 0 -2.3 0.95 0.96
Sampling fraction of cases 0.25
Case-control ratio 1:1 -0.0002 -0.0002 0.16 0.14 0 -1.61 0.96 0.96
Stratified case-control sampling
Sampling fraction of cases 1
Case-control ratio 1:1 -0.0005 -0.0004 0.59 0.53 0 0 0.95 0.96
Sampling fraction of cases 0.5
Case-control ratio 1:1 -0.0005 -0.0004 0.29 0.26 3.48 2.2 0.95 0.96
Sampling fraction of cases 0.25
Case-control ratio 1:1 -0.0003 -0.0001 0.16 0.14 0.86 -1.61 0.95 0.96
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Table 3. Relative risks of the risk factors estimated using information from the control arm of
PLCO Trial and the discovery study. The relative risks for the epidemiologic risk factors (i.e.,
demographics, smoking, lung disease, family history) are obtained from Katki and others (2016)
based on the ever smokers in the control arm of the PLCO trial. The relative risks for the inflam-
mation markers are estimated, after adjustment of other covariates, based on the ever smokers
in the discovery study, a nested case-control study within the screening arm of the PLCO trial.
“Education” was coded as: less than grade 12 = 1, high school graduegeate = 2, post high school
but no college = 3, some college = 4, bachelor’s degree = 5, graduate school = 6. “Quit years”,
i.e., number of years since stopped smoking cigarettes was added as natural logarithm of 1 plus
quit-years. Lung cancer family history was defined as the number of first degree relatives (sib-
lings/parents/children) with history of lung cancer
Relative risk
Epidemiologic Epidemiologic Epidemiologic
Risk factor Coding risk factors risk factors + risk factors +
only CRP 4 inflammation markers
Demographics
Female sex Binary 0.92 0.92 0.92
Race Categorical
White, non-Hispanic 1 [Reference] 1 [Reference] 1 [Reference]
Black, non-Hispanic 1.24 1.24 1.24
Hispanic 0.65 0.65 0.65
Asian or other 0.67 0.67 0.67
Education Trend 0.93 0.93 0.93
BMI Log-term 0.49 0.49 0.49
Smoking
Pack-years Categorical
0-29.9 1 [Reference] 1 [Reference] 1 [Reference]
30-39.9 1.63 1.63 1.63
40-49.9 1.76 1.76 1.76
>50 2.05 2.05 2.05
Quit years Log-term 0.73 0.73 0.73
Years smoked Linear 1.02 1.02 1.02
>1 pack/day Binary 1.36 1.36 1.36
Lung disease
Emphysema/COPD Binary 1.76 1.76 1.76
REFERENCES 15
Table 3 (continued).
Relative risk
Epidemiologic Epidemiologic Epidemiologic
Risk factor Coding risk factors risk factors + risk factors +
only CRP 4 inflammation markers
Family history
Lung cancer Trend 1.52 1.52 1.52
family history
Inflammation
biomarkers
CRP Categorical
Quartile 1 1[Reference] 1 [Reference]
Quartile 2 1.52 1.42
Quartile 3 1.45 1.30
Quartile 4 2.20 1.82
SAA
Quartile 1 1[Reference]
Quartile 2 1.09
Quartile 3 1.32
Quartile 4 1.35
sTNFRII
Quartile 1 1[Reference]
Quartile 2 0.98
Quartile 3 1.13
Quartile 4 0.90
CXCL9/MIG
Quartile 1 1 [Reference]
Quartile 2 0.73
Quartile 3 0.99
Quartile 4 1.03
